Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.7 USD | +1.45% | +3.80% | +3.98% |
May. 06 | Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating | MT |
May. 02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
Evolution of the average Target Price on Bio-Techne Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Bio-Techne Corporation
Argus | |
Scotiabank | |
Leerink Partners | |
UBS | |
Baird | |
RBC Capital Markets | |
Deutsche Bank Securities | |
Stephens Inc. | |
Stifel Nicolaus | |
KeyBanc Capital Markets | |
William Blair & Co. | |
SVB Securities LLC | |
Wells Fargo Securities | |
Citigroup | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- TECH Stock
- Consensus Bio-Techne Corporation